search
Back to results

A Study of SKB315 in Patients With Advanced Solid Tumors

Primary Purpose

Advanced Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SKB315 for injection
Sponsored by
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumors

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patients aged 18 to 80 years (inclusive) at the time of signing the informed consent form (ICF);
  2. Patients with histologically and/or cytologically confirmed advanced solid tumors who have failed standard of care, or who have no available standard of care regimen, or who are unqualified for standard of care;
  3. Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 expression as determined by IHC;
  4. Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
  5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
  6. Estimated survival ≥ 3 months as judged by the investigator;
  7. Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose) ;
  8. Have recovered to ≤ Grade 1 (according to national cancer institute (NCI) common terminology criteria adverse events (CTCAE) V5.0) from previously treated toxicity prior to the first dose of study treatment;
  9. Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing;
  10. Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion Criteria:

  1. Received other drugs in clinical study, major surgeries, or any other anti-tumor therapies within 4 weeks prior to the first dose of study treatment;
  2. Received any previous therapy targeting Claudin18.2;
  3. Plan to receive any other anti-tumor therapy during the study;
  4. Received strong cytochrome P450 3A4(CYP3A4) inhibitors or inducers within 2 weeks prior to the first dose of study treatment or within 5 half-lives of drug elimination, whichever is longer;
  5. Have other malignancies within 5 years prior to signing of ICF;
  6. Pregnant or lactating women;
  7. Known history of allergy to any component of SKB315 or other monoclonal antibodies (mAbs);
  8. Known history of alcohol abuse (consumption of more than 14 units of alcohol per week or drug abuse);
  9. Patients with active hepatitis B or hepatitis C;
  10. Human immunodeficiency virus (HIV) positive;
  11. Active severe digestive disease;
  12. History of major cardiovascular diseases
  13. Confirmed serious lung disease or lung disease that may impair the respiratory reserve function of the patient as judged by the investigator;
  14. History of serious dementia, altered mental status, or any psychiatric disorder;
  15. Concomitant or known metastases to brain or central nervous system;
  16. Have clinically significant systemic diseases that may adversely affect the safety of the study;
  17. Subjects who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study.

Sites / Locations

  • Tianjin Medical University Cancer Institute & HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Phase 1a:Dose escalation

Phase 1b: Dose expansion

Arm Description

Eleven dose levels are tentatively planned for Phase 1a

The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.

Outcomes

Primary Outcome Measures

Phase 1a: Dose Limiting Toxicities (DLT)
Incidence of Dose Limiting Toxicities
Phase 1b: Objective Response Rate (ORR)
The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases.

Secondary Outcome Measures

Progression Free Survival (PFS)
PFS: Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.
Duration of Response (DOR)
DOR: Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.
Overall Survival (OS)
OS: Time from start of treatment to death due to any reason.

Full Information

First Posted
April 21, 2022
Last Updated
October 22, 2023
Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05367635
Brief Title
A Study of SKB315 in Patients With Advanced Solid Tumors
Official Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 16, 2022 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.
Detailed Description
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, PK profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.The study is divided into Phase 1a and Phase 1b: Phase 1a is a dose escalation study to determine the maximum tolerated dose(MTD); Phase 1b is a dose expansion study to conduct preliminary evaluation of anti-tumor efficacy and further evaluation of safety, tolerability, PK, and immunogenicity of SKB315.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
206 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase 1a:Dose escalation
Arm Type
Experimental
Arm Description
Eleven dose levels are tentatively planned for Phase 1a
Arm Title
Phase 1b: Dose expansion
Arm Type
Experimental
Arm Description
The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.
Intervention Type
Drug
Intervention Name(s)
SKB315 for injection
Intervention Description
SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
Primary Outcome Measure Information:
Title
Phase 1a: Dose Limiting Toxicities (DLT)
Description
Incidence of Dose Limiting Toxicities
Time Frame
From data of initial dose until up to 21/28 days for treatment
Title
Phase 1b: Objective Response Rate (ORR)
Description
The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases.
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
PFS: Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.
Time Frame
Up to 2 years
Title
Duration of Response (DOR)
Description
DOR: Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.
Time Frame
Up to 2 years
Title
Overall Survival (OS)
Description
OS: Time from start of treatment to death due to any reason.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients aged 18 to 80 years (inclusive) at the time of signing the informed consent form (ICF); Patients with histologically and/or cytologically confirmed advanced solid tumors who have failed standard of care, or who have no available standard of care regimen, or who are unqualified for standard of care; Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 expression as determined by IHC; Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Eastern Cooperative Oncology Group (ECOG) score of 0 or 1; Estimated survival ≥ 3 months as judged by the investigator; Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose) ; Have recovered to ≤ Grade 1 (according to national cancer institute (NCI) common terminology criteria adverse events (CTCAE) V5.0) from previously treated toxicity prior to the first dose of study treatment; Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing; Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures. Exclusion Criteria: Received other drugs in clinical study, major surgeries, or any other anti-tumor therapies within 4 weeks prior to the first dose of study treatment; Received any previous therapy targeting Claudin18.2; Plan to receive any other anti-tumor therapy during the study; Received strong cytochrome P450 3A4(CYP3A4) inhibitors or inducers within 2 weeks prior to the first dose of study treatment or within 5 half-lives of drug elimination, whichever is longer; Have other malignancies within 5 years prior to signing of ICF; Pregnant or lactating women; Known history of allergy to any component of SKB315 or other monoclonal antibodies (mAbs); Known history of alcohol abuse (consumption of more than 14 units of alcohol per week or drug abuse); Patients with active hepatitis B or hepatitis C; Human immunodeficiency virus (HIV) positive; Active severe digestive disease; History of major cardiovascular diseases Confirmed serious lung disease or lung disease that may impair the respiratory reserve function of the patient as judged by the investigator; History of serious dementia, altered mental status, or any psychiatric disorder; Concomitant or known metastases to brain or central nervous system; Have clinically significant systemic diseases that may adversely affect the safety of the study; Subjects who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yi Ba, Professor
Phone
022-23340123
Email
bayi@tjmuch.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yi Ba, Professor
Organizational Affiliation
Tianjin Medical University Cancer Institute & Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tianjin Medical University Cancer Institute & Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Ba, Professor
Email
bayi@tjmuch.com

12. IPD Sharing Statement

Learn more about this trial

A Study of SKB315 in Patients With Advanced Solid Tumors

We'll reach out to this number within 24 hrs